User login
Key clinical point: Addition of apalutamide to abiraterone and prednisone improves radiographic progression-free survival (rPFS) in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC).
Major finding: At a median follow-up of 54.8 months, apalutamide in combination with abiraterone plus prednisone vs. abiraterone plus prednisone significantly improves rPFS (24.0 months vs 16.6 months; hazard ratio, 0.70; P < .0001).
Study details: A randomized, placebo-controlled, double-blind, phase 3 ACIS study of 982 chemotherapy-naïve patients with mCRPC who were randomly assigned to either apalutamide plus abiraterone and prednisone or abiraterone plus prednisone.
Disclosures: The study received funding from Janssen Research & Development. The authors reported leadership roles and receiving financial support, grants/contracts, consulting fees, and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, and/or educational events from various sources, and/or being employed with and holding stocks in pharmaceutical companies.
Source: Saad F et al. Lancet Oncol. 2021 Sep 30. doi: 10.1016/ S1470-2045(21)00402-2.
Key clinical point: Addition of apalutamide to abiraterone and prednisone improves radiographic progression-free survival (rPFS) in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC).
Major finding: At a median follow-up of 54.8 months, apalutamide in combination with abiraterone plus prednisone vs. abiraterone plus prednisone significantly improves rPFS (24.0 months vs 16.6 months; hazard ratio, 0.70; P < .0001).
Study details: A randomized, placebo-controlled, double-blind, phase 3 ACIS study of 982 chemotherapy-naïve patients with mCRPC who were randomly assigned to either apalutamide plus abiraterone and prednisone or abiraterone plus prednisone.
Disclosures: The study received funding from Janssen Research & Development. The authors reported leadership roles and receiving financial support, grants/contracts, consulting fees, and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, and/or educational events from various sources, and/or being employed with and holding stocks in pharmaceutical companies.
Source: Saad F et al. Lancet Oncol. 2021 Sep 30. doi: 10.1016/ S1470-2045(21)00402-2.
Key clinical point: Addition of apalutamide to abiraterone and prednisone improves radiographic progression-free survival (rPFS) in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC).
Major finding: At a median follow-up of 54.8 months, apalutamide in combination with abiraterone plus prednisone vs. abiraterone plus prednisone significantly improves rPFS (24.0 months vs 16.6 months; hazard ratio, 0.70; P < .0001).
Study details: A randomized, placebo-controlled, double-blind, phase 3 ACIS study of 982 chemotherapy-naïve patients with mCRPC who were randomly assigned to either apalutamide plus abiraterone and prednisone or abiraterone plus prednisone.
Disclosures: The study received funding from Janssen Research & Development. The authors reported leadership roles and receiving financial support, grants/contracts, consulting fees, and payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, and/or educational events from various sources, and/or being employed with and holding stocks in pharmaceutical companies.
Source: Saad F et al. Lancet Oncol. 2021 Sep 30. doi: 10.1016/ S1470-2045(21)00402-2.